Peer-reviewed Medical Research Using Withings Devices Reveals Body Composition Predicts GLP-1 Weight Loss Outcomes

person standing on white digital bathroom scale

Withings, a pioneer in clinical-grade connected health devices, today announced the publication of a peer-reviewed study in Mayo Clinic Proceedings providing a real-world analysis of how body composition changes in individuals using GLP-1 receptor agonist therapy. The study found that the majority of weight lost during treatment comes from fat rather than muscle, while underscoring that individuals begin GLP-1 therapy with different body composition, reinforcing the importance of personalised monitoring throughout treatment.

GLP-1 medications are prescribed at scale across the UK, and one fear dominates the conversation: the medications eliminate muscle along with fat. Using causal-inference methods and a matched comparison group, this is one of the first studies to show what actually happens to body composition in a large, diverse, real-world population.

In the UK, GLP-1 medicines such as Wegovy and Mounjaro are now prescribed both through the NHS and via private and online pharmacy pathways, putting body-composition monitoring within reach of a fast-growing group of patients and clinicians.

Fat versus muscle loss during GLP-1 treatment

Across 396 GLP-1 users and 1,635 matched controls, starting treatment was associated with a median 9.8% reduction in total body weight over one year, about 10.2 kg per person, compared with matched non-users. Of that weight loss, 7.5% came from fat mass versus just 2.3% in muscle. Put another way, muscle accounted for 21.6% of the total weight lost, comparable to the roughly 25% attributed to weight loss from dieting2. This demonstrated that the quality of weight loss on GLP-1s in this real-world population was at least as good as under a calorie-restricted diet. Blood pressure also improved, with systolic blood pressure falling about 2.5 mm Hg and diastolic pressure about 1.5 mm Hg. This was consistent even through the winter months, when blood pressure typically rises, a pattern visible only through frequent at-home monitoring. But these are averages, and the study shows they hide wide differences: some people lose far more muscle than others. For most, the weight coming off is largely the right kind, but “most” is not “everyone.”

Research reveals that starting body composition predicts fat and muscle loss

The study’s most original finding is that, among all the baseline factors it looked at (age, gender, BMI, and muscle-to-fat ratio), your starting muscle-to-fat ratio was the most consistent signal of weight-loss quality. People who start with more fat relative to muscle tend to lose more fat and spare more muscle, while those who start leaner lose proportionally more muscle. A simple body-composition reading before starting treatment can show which group you’re closer to, and how closely to watch.

Agathe Chabassier, RWE Data Scientist at Withings: “One of the big fears with GLP-1s has always been muscle loss. For most people, most of the weight lost is fat. But averages hide big differences. Some people lose far more muscle than others. Your body composition before you start helps flag who’s most at risk, and tracking it during treatment can catch an unhealthy loss early.”

Body composition after GLP-1 treatment

The Withings smart scales at the centre of this study did more than measure weight: they tracked fat mass and muscle mass separately throughout treatment, giving researchers the granular picture that made this analysis possible. That same capability is valuable after treatment ends. Separate research has shown that weight often returns after stopping GLP-1 therapy, and that what comes back is not always what left: regained weight can skew toward fat rather than muscle (external literature, e.g. UC Davis Health; not a finding of this study).1 Tracking body composition, not just total weight, during and after treatment gives users and their doctors the information they need to act early, whether that means adjusting protein intake, adding resistance training, or revisiting the care plan.